Phaseline

Companies › Swedish Orphan Biovitrum

Swedish Orphan Biovitrum: clinical trials, targets and expected readouts

4 active drug programs in 36 registered trials: 19 Phase 2, 9 Phase 1, 5 Phase 3, 3 Phase 4; Hematology, Immunology, Oncology, Cardiovascular; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Efanesoctocog alfa
Coagulation factor VIII exogenous protein
F8Phase 4Haemophilia A (Moderate or Severe); Hemophilia ANov 2026
Pegcetacoplan
Complement C3 inhibitor
C3Phase 4C3 Glomerulopathy (C3G)Dec 2031
Pacritinib
Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor
JAK2, FLT3, ACVR1, IRAK1Phase 3Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia …Dec 2026
Anakinra
Interleukin-1 receptor antagonist
IL1R1Phase 3Still's Disease, Juvenile Onset; FMF; Kawasaki Disease; Premature Infants …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05814159AnakinraPhase 3Still's Disease, Juvenile OnsetImmunologyDec 2025
NCT04520269PacritinibPhase 1Breast CancerOncologyJul 2026
NCT06752850Efanesoctocog alfaPhase 4Haemophilia A (Moderate or Severe)HematologyNov 2026
NCT06336733AnakinraPhase 3FMFOtherDec 2026
NCT07254000AnakinraPhase 2Premature InfantsImmunologyDec 2026
NCT06782373PacritinibPhase 2VEXASHematologyDec 2026
NCT03587701AnakinraPhase 2Autoimmune Inner Ear DiseaseImmunologyDec 2026
NCT03645824PacritinibPhase 2MyelofibrosisOncologyFeb 2027
NCT05177822AnakinraPhase 2Heart FailureCardiovascularFeb 2027
NCT06716814Efanesoctocog alfaPhase 3Haemophilia A (Moderate or Severe)HematologyMar 2027
NCT04656184AnakinraPhase 3Kawasaki DiseaseImmunologyMar 2027
NCT06538181PacritinibPhase 1E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic SyndromeImmunologyMar 2027
NCT04926467AnakinraPhase 2Pancreatic AdenocarcinomaOncologyJun 2027
NCT06159491PacritinibPhase 1Chronic Myelomonocytic LeukemiaOncologyJul 2027
NCT05531786PacritinibPhase 1Graft vs Host DiseaseImmunologyJul 2027
NCT04148430AnakinraPhase 2B Cell ALLOncologyOct 2027
NCT04282187PacritinibPhase 2Acute Myeloid LeukemiaOncologyNov 2027
NCT04858256PacritinibPhase 2T-Cell NeoplasmOncologyNov 2027
NCT07394153PacritinibPhase 2Myelofibrosis,MFOncologyDec 2027
NCT05611710AnakinraPhase 2DengueInfectious diseaseDec 2027
NCT06675123PacritinibPhase 1Recurrent Mantle Cell LymphomaOncologyMar 2028
NCT05926505AnakinraPhase 2Post-Acute COVID-19 SyndromeInfectious diseaseMar 2028
NCT05267821AnakinraPhase 2Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)Infectious diseaseMay 2028
NCT06381661AnakinraPhase 2SepsisInfectious diseaseAug 2028
NCT06986174PacritinibPhase 2Waldenström MacroglobulinemiaOncologyOct 2028
NCT03165734PacritinibPhase 3Primary MyelofibrosisHematologyOct 2028
NCT06940830Efanesoctocog alfaPhase 4Hemophilia AHematologyDec 2028
NCT07148947PacritinibPhase 2Accelerated Phase Myeloproliferative NeoplasmOncologyDec 2028
NCT07226713PacritinibPhase 2Prostate CancerOncologyMar 2029
NCT07503834AnakinraPhase 1Pancreatic TransplantImmunologyApr 2029
NCT06218628PacritinibPhase 1Primary MyelofibrosisOncologyAug 2029
NCT06303193PacritinibPhase 1Myelodysplastic SyndromesHematologyJan 2030
NCT07447817PacritinibPhase 2MyelofibrosisHematologyMay 2030
NCT05013450AnakinraPhase 1Metastatic Non-small Cell Lung CancerOncologySep 2030
NCT07746895PegcetacoplanPhase 4C3 Glomerulopathy (C3G)GenitourinaryDec 2031
NCT06052618PacritinibPhase 2KSHV Inflammatory Cytokine Syndrome (KICS)OncologyJan 2033

From the company's SEC filings

Complete response letters from FDA

Targets

F8 (1) IL1R1 (1) JAK2 (1) FLT3 (1) ACVR1 (1) IRAK1 (1) C3 (1)

Companies with the same targets

Theradex Pfizer Roche Bristol-Myers Squibb AbbVie GSK Daiichi Sankyo Sinocelltech Octapharma ASC Therapeutics

Companies built like this

Octapharma Jiangsu vcare pharmaceutical technology Bausch Health Americas Brainfarma Industria Química e Farmacêutica S/A Servier Affaires Médicales

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.